Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 2 to \<18 years old.~* Diagnosis of Gaucher disease with leukocyte acid β-glucosidase activity ≤30% of the mean of the reference range for healthy subjects.~* Subjects who have not received enzyme replacement therapy (ERT) in the past or who have not received ERT in the past 12 months and have a negative anti-glucocerebrosidase antibody assay.~* Subjects who have not received substrate reduction therapy (SRT) in the past 12 months.~* Subjects whose clinical condition, in the opinion of the investigator, requires treatment with enzyme replacement therapy (ERT).~Exclusion Criteria:~* Currently taking another investigational drug for any condition.~* Presence of neurological signs and symptoms characteristic of Gaucher disease with complex neuronopathic features other than longstanding oculomotor gaze palsy.~* Presence of unresolved anemia due to iron, folic acid, or vitamin B12 deficiency~* Previous hypersensitivity reaction to Cerezyme® (imiglucerase) or Ceredase® (alglucerase).~* History of allergy to carrots.~* Presence of HIV, HBsAg or hepatitis C infections.~* Subject's parent(s) or legal guardian(s) are unable to understand the nature, scope and possible consequences of the study.~* Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 30 units/kg (Type: EXPERIMENTAL): None
- 60 units/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).